#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	5636	16S	1529	1529	99.93	16S.l15.c4.ctg.1	1985	479.7	0	.	n	.	0	C1450T	SNP	1450	1450	C	1720	1720	T	495	T,A	285,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	5636	16S	1529	1529	99.93	16S.l15.c4.ctg.1	1985	479.7	1	SNP	n	C1184T	0	.	.	1184	1184	C	1454	1454	C	624	C,A	351,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	9674	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3490	455.3	0	.	n	.	0	A9G	SNP	9	9	A	243	243	G	494	G	286	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	9674	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3490	455.3	0	.	n	.	0	T695C	SNP	695	695	T	929	929	C	501	C	288	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	9674	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3490	455.3	0	.	n	.	0	T1971C	SNP	1971	1971	T	2205	2205	C	443	C	248	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	9674	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3490	455.3	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	2831	2831	T	457	T	264	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	9674	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3490	455.3	1	SNP	n	A2045G	0	.	.	2045	2045	A	2279	2279	A	480	A	277	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	9674	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3490	455.3	0	HET	.	.	.	A412G	.	412	412	A	646	646	A	416	A,G	195,40	.	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	27	354	folP	855	855	99.77	folP.l15.c4.ctg.1	1553	41.0	1	SNP	p	R229S	1	.	.	685	687	AGC	949	951	AGC	52;52;54	A;G;C	32;34;33	folP.WHO_Y_01480c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	974	gyrA	2751	2751	99.78	gyrA.l15.c4.ctg.1	3461	44.8	0	.	p	.	0	T243I	NONSYN	727	729	ACA	1001	1003	ATA	63;60;52	A;T;A	35;35;29	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	974	gyrA	2751	2751	99.78	gyrA.l15.c4.ctg.1	3461	44.8	0	.	p	.	0	M250I	NONSYN	748	750	ATG	1022	1024	ATA	48;48;48	A;T;A	26;25;26	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	974	gyrA	2751	2751	99.78	gyrA.l15.c4.ctg.1	3461	44.8	1	SNP	p	S91F	0	.	.	271	273	TCC	545	547	TCC	84;84;84	T;C;C	46;49;50	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	974	gyrA	2751	2751	99.78	gyrA.l15.c4.ctg.1	3461	44.8	1	SNP	p	D95G	0	.	.	283	285	GAC	557	559	GAC	86;86;86	G;A;C	48;49;48	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	974	gyrA	2751	2751	99.78	gyrA.l15.c4.ctg.1	3461	44.8	1	SNP	p	D95N	0	.	.	283	285	GAC	557	559	GAC	86;86;86	G;A;C	48;49;48	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	531	270	mtrR	633	633	99.69	mtrR.l6.c17.ctg.1	1204	37.8	0	.	p	.	0	P191fs	FSHIFT	571	571	C	968	968	C	42	C	25	.	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	531	270	mtrR	633	633	99.69	mtrR.l6.c17.ctg.1	1204	37.8	1	SNP	p	G45D	0	.	.	133	135	GGC	529	531	GGC	68;68;69	G;G;C	38;38;38	mtrR.WHO_U_01459:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	164	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c30.ctg.1	952	29.1	0	.	n	.	0	.206T	INS	206	206	T	569	569	T	70	T	40	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	834	parC	2304	2304	99.74	parC.l15.c4.ctg.1	2909	49.0	0	.	p	.	0	V421A	NONSYN	1261	1263	GTC	1553	1555	GCC	65;63;59	G;C;C	40;39;34	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	834	parC	2304	2304	99.74	parC.l15.c4.ctg.1	2909	49.0	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1595	1597	GCA	54;55;55	G;C;A	34;35;35	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	834	parC	2304	2304	99.74	parC.l15.c4.ctg.1	2909	49.0	1	SNP	p	D86N	0	.	.	256	258	GAC	548	550	GAC	80;80;80	G;A;C	46;43;48	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	834	parC	2304	2304	99.74	parC.l15.c4.ctg.1	2909	49.0	1	SNP	p	S87W	0	.	.	259	261	AGT	551	553	AGT	79;79;79	A;G;T	47;45;46	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	834	parC	2304	2304	99.74	parC.l15.c4.ctg.1	2909	49.0	1	SNP	p	S87R	0	.	.	259	261	AGT	551	553	AGT	79;79;79	A;G;T	47;45;46	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	834	parC	2304	2304	99.74	parC.l15.c4.ctg.1	2909	49.0	1	SNP	p	S87I	0	.	.	259	261	AGT	551	553	AGT	79;79;79	A;G;T	47;45;46	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	834	parC	2304	2304	99.74	parC.l15.c4.ctg.1	2909	49.0	1	SNP	p	S88P	0	.	.	262	264	TCC	554	556	TCC	79;78;77	T;C;C	46;47;47	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_W_01411c	parE.WHO_W_01411c	1	1	27	824	parE	1986	1986	99.95	parE.l6.c4.ctg.1	3090	45.8	1	SNP	p	G410V	0	.	.	1228	1230	GGT	1756	1758	GGT	53;54;54	G;G;T	35;31;29	parE.WHO_W_01411c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.22.001	penA.22.001	1	1	283	1046	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2599	65.8	1	SNP	p	A311V	0	.	.	931	933	GCA	1187	1189	GCA	104;104;104	G;C;A	59;59;59	penA.22.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	283	1046	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2599	65.8	1	SNP	p	I312M	0	.	.	934	936	ATC	1190	1192	ATC	105;105;105	A;T;C	60;60;61	penA.22.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	283	1046	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2599	65.8	1	SNP	p	V316P	0	.	.	946	948	GTG	1202	1204	GTG	111;112;112	G;T;G	63;61;64	penA.22.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	283	1046	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2599	65.8	1	SNP	p	V316T	0	.	.	946	948	GTG	1202	1204	GTG	111;112;112	G;T;G	63;61;64	penA.22.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	283	1046	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2599	65.8	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1706	1708	ACC	49;49;49	A;C;C	30;30;32	penA.22.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	283	1046	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2599	65.8	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1760	1762	GCG	45;46;46	G;C;G	25;24;27	penA.22.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	283	1046	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2599	65.8	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1760	1762	GCG	45;46;46	G;C;G	25;24;27	penA.22.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	283	1046	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2599	65.8	1	SNP	p	G543S	0	.	.	1627	1629	GGT	1883	1885	GGT	68;68;67	G,C;G;T	38,1;38;38	penA.22.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	283	1046	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2599	65.8	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1892	1894	GGC	65;65;65	G;G;C	37;35;36	penA.22.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	283	1046	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2599	65.8	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1910	1912	CCG	66;66;66	C;C;G	37;38;37	penA.22.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	1928	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	2920	103.6	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	418	porA	1146	1146	99.65	porA.l15.c4.ctg.1	1740	42.2	0	.	p	.	0	S22G	NONSYN	64	66	AGC	424	426	GGC	62;62;62	G;G;C	38;37;37	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	418	porA	1146	1146	99.65	porA.l15.c4.ctg.1	1740	42.2	0	.	p	.	0	M83fs	FSHIFT	247	247	A	606	606	C	33	C	20	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	520	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	1544	61.2	0	.	p	.	0	T18M	NONSYN	52	54	ACG	272	274	ATG	63;63;67	A;T;G	36;36;39	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	520	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	1544	61.2	0	.	p	.	0	E48G	NONSYN	142	144	GAA	362	364	GGA	60;60;60	G;G;A	36;36;37	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	520	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	1544	61.2	0	.	p	.	0	V75I	NONSYN	223	225	GTT	443	445	ATT	75;75;73	A;T;T	47;46;46	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	520	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	1544	61.2	0	.	p	.	0	T89S	NONSYN	265	267	ACC	485	487	AGC	74;74;68	A;G;C	43;44;41	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	520	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	1544	61.2	0	.	p	.	0	V98I	NONSYN	292	294	GTC	512	514	ATC	60;59;59	A;T;C	36;36;36	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	520	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	1544	61.2	0	.	p	.	0	.	MULTIPLE	358	359	AA	577	578	CG	48;48	C;G	32;32	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	520	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	1544	61.2	0	.	p	.	0	.	MULTIPLE	361	362	GA	580	582	CAG	48;50;50	C;A;G	33;33;33	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	520	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	1544	61.2	0	.	p	.	0	N122K	NONSYN	364	366	AAC	584	586	AAA	51;51;51	A;A;A	34;34;29	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	520	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	1544	61.2	0	.	p	.	0	F131Y	NONSYN	391	393	TTT	611	613	TAT	56;56;56	T;A;T	35;37;35	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	520	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	1544	61.2	0	.	p	.	0	N134K	NONSYN	400	402	AAT	620	622	AAG	51;51;52	A;A;G	34;35;36	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	520	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	1544	61.2	0	.	p	.	0	V135F	NONSYN	403	405	GTG	623	625	TTT	52;52;52	T;T;T	36;36;34	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	520	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	1544	61.2	0	.	p	.	0	G140K	NONSYN	418	420	GGA	638	640	AAA	51;51;51	A;A;A	34;32;35	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	520	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	1544	61.2	0	.	p	.	0	K143E	NONSYN	427	429	AAA	647	649	GAA	54;56;56	G;A;A	37;36;37	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	520	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	1544	61.2	0	.	p	.	0	V151A	NONSYN	451	453	GTA	671	673	GCA	60;60;60	G;C;A	40;39;35	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	520	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	1544	61.2	0	.	p	.	0	T213S	NONSYN	637	639	ACA	857	859	TCA	89;95;94	T;C;A	49;53;52	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	520	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	1544	61.2	0	.	p	.	0	G253Q	NONSYN	757	759	GGA	977	979	CAA	82;82;82	C;A;A	47;47;48	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	520	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	1544	61.2	0	.	p	.	0	.	INDELS	760	762	ACA	981	985	ATCAA	82;82;81;79;79	A;T;C;A;A	46;49;45;43;46	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	520	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	1544	61.2	0	.	p	.	0	.	INDELS	763	764	TG	988	990	AGT	79;79;78	A;G;T	46;46;43	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	520	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	1544	61.2	0	.	p	.	0	A257D	NONSYN	769	771	GCT	995	997	GAT	84;85;85	G;A;T	46;46;47	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	520	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	1544	61.2	0	.	p	.	0	T269S	NONSYN	805	807	ACC	1031	1033	AGC	90;90;90	A;G;C	48;49;49	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	520	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	1544	61.2	0	.	p	.	0	D293S	NONSYN	877	879	GAT	1103	1105	AGT	94;96;93	A;G;T	54;55;51	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	520	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	1544	61.2	0	.	p	.	0	N295D	NONSYN	883	885	AAC	1109	1111	GAC	90;89;90	G;A;C	53;51;53	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	520	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	1544	61.2	0	.	p	.	0	H296Y	NONSYN	886	888	CAC	1112	1114	TAC	90;90;92	T;A;C	52;52;55	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	520	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	1544	61.2	1	SNP	p	G120K	1	.	.	358	360	AAG	577	579	CGG	48;48;48	C;G;G	32;32;30	porB1b.WHO_M_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	520	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	1544	61.2	1	SNP	p	D121N	0	.	.	361	363	GAC	580	583	CGC	48;50;51	C;G;C	33;33;35	porB1b.WHO_M_02204c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	520	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	1544	61.2	1	SNP	p	A121D	1	.	.	361	363	GAC	580	583	CGC	48;50;51	C;G;C	33;33;35	porB1b.WHO_M_02204c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	2942	rpoB	4179	4179	99.98	rpoB.l6.c17.ctg.1	4611	104.8	1	SNP	p	H553N	0	.	.	1657	1659	CAT	1824	1826	CAT	133;133;133	C;A;T	77;77;78	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	216	rpsJ	312	312	100.0	rpsJ.l15.c17.ctg.1	952	39.3	1	SNP	p	V57M	1	.	.	169	171	ATG	530	532	ATG	66;64;68	A;T;G	40;37;41	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
